Admilparant

Summary

Admilparant (CHEMBL5087506) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including idiopathic pulmonary fibrosis and pulmonary fibrosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 18
• Chemistry: 445.5 Da · C22H31N5O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5087506
Name	Admilparant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	132232205
Molecular formula	C22H31N5O5
Molecular weight	445.5
InChIKey	UEUNDURNLYLSNB-HOTGVXAUSA-N

SMILES: CCCN(C)C(=O)OCC1=C(N=NN1C)C2=NC(=C(C=C2)O[C@H]3CCC[C@@H](C3)C(=O)O)C

IUPAC name: trans-(1S,3S)-3-[[2-methyl-6-[1-methyl-5-[[methyl(propyl)carbamoyl]oxymethyl]triazol-4-yl]-3-pyridinyl]oxy]cyclohexane-1-carboxylic acid

Also known as: Admilparant, BMS-986,278, Bms-986278, BMS-986278, BMS986278, ADMILPARANT

Patent coverage: 32 distinct patent families (71 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, ATP-binding cassette sub-family C member 4, ATP-binding cassette sub-family C member 3.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLCO1B3	5	IC50	10000	nM	CHEMBL_ACT_24366043

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
idiopathic pulmonary fibrosis	3	MONDO:0800504	EFO:0000768
pulmonary fibrosis	3	MONDO:0002771	EFO:0009448
interstitial lung disease	1	MONDO:0015925	HP:0006515
liver disorder	1	MONDO:0005154	EFO:0001421

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE1	14
PHASE3	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06003426	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06025578	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT07441408	PHASE3	NOT_YET_RECRUITING	Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT04308681	PHASE2	COMPLETED	A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
NCT07422298	PHASE1	RECRUITING	A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
NCT03429933	PHASE1	COMPLETED	A Study of Experimental Medication BMS-986278 Given to Healthy Participants
NCT03712540	PHASE1	COMPLETED	An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
NCT03981094	PHASE1	COMPLETED	A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
NCT04468815	PHASE1	COMPLETED	A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)
NCT04567667	PHASE1	COMPLETED	Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants
NCT05684289	PHASE1	COMPLETED	A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
NCT05805904	PHASE1	COMPLETED	A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
NCT05932303	PHASE1	COMPLETED	A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
NCT05985590	PHASE1	COMPLETED	A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
NCT06425198	PHASE1	COMPLETED	Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
NCT06723535	PHASE1	COMPLETED	A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
NCT06746402	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
NCT07225647	PHASE1	COMPLETED	A Study to Assess the Effect of Food on the Drug Levels of Admilparant

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).